好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

A Systematic Review of Pain Phenotypes in Individuals with Parkinson's Disease
Pain
P4 - Poster Session 4 (5:00 PM-6:00 PM)
7-010
 Identify the types of pain experienced by individuals with PD and beneficial treatment options.

Therapeutic modalities encompass a spectrum ranging from pharmacological interventions to surgical procedures such as deep brain stimulation (DBS). Reported success rates of these interventions in alleviating pain symptoms associated with Parkinson's Disease (PD) vary notably. There is a need to delve into real-world scenarios to comprehensively comprehend the prevalence of pain in PD, explore the breadth of available treatment modalities—both surgical and non-surgical—and discern factors that might predict more favorable responses to these interventions.

We systematically reviewed the features of pain in Parkinson's disease (PD) by searching databases like PubMed, Europe PMC, and SCOPUS until October 4, 2024, using the terms "Parkinson disease," "Parkinsonism," and "pain." We evaluated all selected studies for bias using the ROBINS-I tool and followed the PRISMA guideline for conducting the study.

Musculoskeletal pain predominates in PD constituting 40%— 90% of reported cases. It correlates with parkinsonian rigidity, akinesia, postural abnormalities, or dystonia, often accentuated on the side with prominent motor symptoms. Pain linked to akinesia may occur nocturnally, necessitating differentiation from restless leg syndrome. Approximately 4%—10% of PD patients experience pain directly attributed to the disease. Central Parkinson pain varies between intermittent and persistent, characterized by diffuse sensations like aching, burning, or cramping. Radicular pain prevalence in PD ranges from 14% to 35%, exceeding the general population's 10%.

Through a deepened understanding of the occurrence and consequences of chronic pain in PD, alongside its ramifications on patient well-being, novel methodologies and strategies can be devised to enhance patient outcomes. By delving into biomarkers, we can explore predictive indicators to discern individuals who are likely to benefit from DBS for alleviating chronic pain symptoms. Additionally, this exploration can help identify those who may necessitate supplementary therapeutic interventions to achieve effective symptom relief.

Authors/Disclosures
Saurabh Kataria, MD (Pier Landing)
PRESENTER
Dr. Kataria has nothing to disclose.
Utsav Patel Utsav Patel has nothing to disclose.
Alexander Erick Purnomo (University of Pelita Harapan, Karawaci, Tangerang, Banten, Indonesia) No disclosure on file
Made A. Inggas, MD, PhD Dr. Inggas has nothing to disclose.
Prakriti Arya, MBBS Dr. Arya has nothing to disclose.
Sanidhya Karve, MD Dr. Karve has nothing to disclose.
Tawfiq Turjman, MS Mr. Turjman has nothing to disclose.
Hisham Turjman, MS Mr. Turjman has nothing to disclose.
Muhammad Khalid, MD (LSU shreveport) Dr. Khalid has nothing to disclose.
Alan Kaye (LSUHSC Sghreveport) Alan Kaye has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Heliyon Journal. Alan Kaye has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Pain Physician Journal. Alan Kaye has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Current Pain and Headache Reports.